Back
About the Global Fund
People & Structures
Back
Funding Model
Investments & Results
-
Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
- Data Explorer
- Funding Decisions
- Data Service
HIV & AIDS
Tuberculosis
Malaria
Back
News
-
08 April 2021
Global Fund Thanks Germany for EUR 140 million Contribution -
24 March 2021
TB testing in 2020 dropped drastically due to COVID-19 -
18 March 2021
Nigeria and Global Fund Launch New Grants to Fight HIV, TB and Malaria -
18 March 2021
Gavi, the Global Fund and USAID announce innovative collaboration to support supply chain leaders
Updates
Stories
-
24 March 2021
On World TB Day, Crisis and Hope -
24 March 2021
Fighting Two Airborne Pandemics in India: TB and COVID-19 -
23 March 2021
Uganda’s Remarkable Response to COVID-19 -
08 March 2021
Women Leading the Charge to End Diseases -
01 March 2021
El Salvador Triumphs Over Malaria -
22 February 2021
Country dialogue during the pandemic: Indonesia shows the virtual way
Back
Featured Publication
Documents by type
Opportunity for Evaluation of Selected Medicines
20 November 2020
The Global Fund, Stop TB Partnership Global Drug Facility and Unitaid are inviting manufacturers of antiretroviral (HIV/AIDS), antihepatitis B and C, antituberculosis and antimalarial medicines to submit an expression of interest to have their products evaluated by the Expert Review Panel for Pharmaceutical Products.
Detailed information about the review process and submission requirements for this Round 23 opportunity can be found in the document below.
Once all expressions of interest have been received, the Expert Review Panel will be responsible for reviewing and judging their eligibility and whether to perform a risk-benefit assessment of the products submitted.
The deadline for submission of an expression of interest is Friday 08 January 2021 (COB). At the end of January 2021, the Global Fund Secretariat will communicate to manufacturers the outcomes of the review of the completeness of documents submitted. The results of the product evaluations are expected for release by the end of March 2021.
- Invitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical ProductsInvitation to Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial Medicines Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
download in English
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.